옵션 체인은 다양한 행사가격과 만기일에 대한 Surmodics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Surmodics에 대한 시장 심리를 평가합니다..

Surmodics (NASDAQ:SRDX) 주식, 옵션 체인

Surmodics

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

benzinga_deal_dispatch2

Asset Sales

ALGM

CSAN

SHEL

SRDX

새로운 소식 라이젠(Raizen)은 쉘(NYSE:SHEL)과 코산(NYSE:CSAN) 간의 브라질 합작 회사로, JP모건을 통해 아르헨티나 석유 정유소와 주유소 네트워크 매각을 추진하고 있다. 블룸버그는 최근 CEO 넬슨 고메스(Nelson Gomes)의 애널리스트와의 실적 발표 전화에서의 발언을 인용하여, 이 회사가 &#34;심층적인&#34; 포트폴리오 개편을 진행 중이라고 보도했다.

딜 디스패치: 틱톡의 시계가 똑딱똑딱, 라이젠이 자산 매각을 탐색, 월그린스의 사기업 전환

Surmodics Inc

Lake Street analyst Brooks O'Neil upgrades Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) from Hold to Buy and maintains the price target from $43 to $43.

News

Upgrades

Price Target

Analyst Ratings

Lake Street Upgrades Surmodics to Buy, Maintains Price Target to $43

<h2 class="wp-block-heading">New On The Block</h2>
Raizen, a Brazilian joint venture between Shell plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) and Cosan SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>), tapped JPMorgan to shop around its Argentinian oil refinery and gas stations network. Bloomberg recently <a href="https://www.bloomberg.com/news/articles/2025-03-06/raizen-is-said-to-hire-jpmorgan-for-argentina-energy-assets-sale?srnd=phx-deals">reported</a> that the company is undergoing a "profound" portfolio revision, citing CEO Nelson Gomes&#8216;s comments to analysts during an earnings call.
<h2 class="wp-block-heading">Updates From The Block</h2>
Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) may be heading to the private sector, thanks to a $10 billion deal with Sycamore Partners. The transaction, approved by Walgreens&#8217; board, offers shareholders $11.45 per share in cash. Gary Black of The Future Fund LLC shared the news on social media, quipping, "I've talked before about how this company shouldn't be public." And who's pulling the strings? Executive chairman Stefano Pessina, who owns a 16.9% stake and clearly decided it was time to take his pharmacy empire <a href="https://www.benzinga.com/markets/equities/25/03/44185847/gary-black-says-walgreens-is-a-company-that-shouldnt-be-public-cites-largest-shareholders-role-in-10-billion-sycamore-deal">out of the public eye</a>.
President Donald Trump wants a U.S. sovereign wealth fund to buy TikTok&#8216;s U.S. business. That&#8217;s a bit like suggesting that a college student who is knee-deep in loans save up for a private jet. U.S. debt is exorbitant and the Trump administration is (they say) <a href="https://www.benzinga.com/news/25/03/44143475/trumps-u-s-doge-service-claims-65b-in-savings-experts-call-it-smoke-and-mirrors-amid-resignations">focused on reducing it</a>. However, <a href="https://www.reuters.com/markets/wealth/dealmaker-michael-grimes-expected-lead-new-us-sovereign-wealth-fund-sources-say-2025-03-05/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axiosprorata&amp;stream=top">Reuters</a> is reporting that Morgan Stanley&#8216;s Michael Grimes, who helped steer the Uber IPO and the Twitter takeover, is overseeing the formation of a sovereign wealth fund for Uncle Sam. But with TikTok&#8217;s April 5 deadline looming, time is of the essence. Tick tock. Pun intended.
Sure, a deal could get signed by then, but each passing day makes it feel more like a Hail Mary pass—except this time, instead of catching a football, the U.S. is hoping to catch a lip-syncing, trendsetting social media giant.
Meanwhile, Onsemi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) upped its bid for Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) to acquire the company for $35.10 per share, valuing the deal at $6.9 billion. This represents an increase over an initial $34.50 per share proposal submitted on Sept. 2.
<h2 class="wp-block-heading">Off The Block</h2>
American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) agreed to acquire Bellevue, Wash.-based Center, according to <a href="https://www.bloomberg.com/news/articles/2025-03-06/american-express-to-acquire-expense-management-company-center?srnd=phx-deals">Bloomberg</a>. Center is a software provider backed by Durable Capital Partners, Top Tier Capital Partners and Mango Capital.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Canoo, the electric vehicle startup that never quite got rolling, is getting a reboot—from its own CEO, no less. Anthony Aquila is buying nearly all of Canoo's assets out of bankruptcy for $4 million in cash, per <a href="https://techcrunch.com/2025/03/05/canoos-ceo-is-buying-the-bankrupt-ev-startups-assets/">TechCrunch</a>. The sale is expected to erase the $11 million debt Canoo owes to a financial firm&#8230; conveniently run by Aquila himself. Canoo filed for Chapter 7 liquidation just six weeks ago. Government contracts with NASA and the Department of Defense bore little fruit. The startup has roughly $145 million in assets but $175 million in liabilities. Now, other buyers can still throw their hats in the ring before March 28.
<h2 class="wp-block-heading">Notes From The Block</h2>
So much for the wave of M&amp;A dealmakers expected with Trump&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">return to the White House</a>. 
They banked on <a href="https://in.benzinga.com/news/25/02/44045159/trumps-plan-to-rein-in-regulators-could-erode-market-trust-says-2-3-trillion-asset-manager">looser regulations</a> and a more <a href="https://www.benzinga.com/25/03/44197558/whats-moving-markets-friday">vibrant stock market</a>. So far, neither scenario has come to fruition. According to Dealogic, U.S.-based M&amp;A volume is down about 29% compared to this timeframe in 2024. 
Consider the Federal Trade Commission&#8217;s (FTC) latest move. The agency, with a Trump appointee at the helm, is throwing a wrench into a private equity firm's plan to acquire Surmodics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a company that specializes in drug delivery and in vitro diagnostic technologies.
The buyer, GTCR, already owns Biocoat, a Surmodics rival. Owning both would give them over 50% market control and the ability to squash competition. And the cost of the tech would indeed hurt the consumer. Since it's unlikely a new competitor would rise to challenge the dynamic duo of Biocoat and Surmodics, the FTC has taken the matter to court in the Northern District of Illinois.
For those surprised that the Trump administration isn&#8217;t letting this merger slide, recall his first term when the Department of Justice blocked deals between AT&amp;T and Time Warner; Sinclair and Tribune Media; Broadcom and Qualcomm as well as DraftKings and FanDuel.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/03/44110974/halle-berry-launches-a-new-business-venture-succeeds-with-netflix-and-doubles-down-on-her-luxury-malibu-home">Halle Berry Launches A New Business Venture, Succeeds With Netflix, And Doubles Down On Her Luxury Malibu Home</a></li>
</ul>
For last week&#8217;s edition of <a href="https://www.benzinga.com/news/asset-sales/25/02/43897289/deal-dispatch-hooters-plans-restructuring-prada-in-talks-to-acquire-versace">Deal Dispatch, click here</a>.

Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower in the premarket session on Friday.</a>
The firm&#8217;s stock dipped following news that the U.S. Federal Trade Commission will challenge the proposed acquisition by funds <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44183928/surmodics-issues-statement-on-u-s-federal-trade-commission-challenge-to-proposed-acquisition-of-su" rel="noreferrer noopener">affiliated with private equity firm GTCR LLC.</a>
GTCR has an equity investment in Biocoat Inc., a medical coatings manufacturer, which raised concerns for the FTC.
&#8220;The FTC charges that private equity firm GTCR's proposed acquisition of Surmodics would create a combined company controlling more than 50% of the market for outsourced hydrophilic coatings. These coatings are often used by medical device manufacturers and are applied to lifesaving medical devices such as catheters and guidewires,&#8221; the regulatory body said in a <a href="https://www.ftc.gov/news-events/news/press-releases/2025/03/ftc-challenges-medical-device-coatings-deal">release</a>.
The FTC's complaint argues that making hydrophilic coatings requires specialized expertise and significant investment and many OEMs prefer outsourcing to established companies like Biocoat and Surmodics.
After the merger, it's unlikely a new competitor could challenge GTCR and Surmodics.
In response to the FTC&#8217;s announcement, Surmodics issued a statement expressing its disagreement with the agency&#8217;s decision.
The company emphasized its commitment to completing the merger and remains confident in the deal&#8217;s potential to benefit all stakeholders, including shareholders, customers and patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44186784/copt-defense-properties-faces-risks-analyst-sees-uncertainty-in-leasing-process-amid-budget-cut-risks" rel="noreferrer noopener">COPT Defense Properties Faces Risks: Analyst Sees Uncertainty In Leasing Process Amid Budget Cut Risks</a>
The FTC&#8217;s complaint particularly states that GTCR's acquisition of Surmodics would raise market concentration in the hydrophilic coatings sector, which already has few competitors, violating the 2023 Merger Guidelines.
However, Surmodics said it has worked closely with the FTC for months to secure regulatory approval and voiced disappointment over the agency&#8217;s move to initiate litigation.
The company asserts that the merger is &#8220;pro-competitive&#8221; and says intends to vigorously defend the case in court.
Surmodics entered into a definitive <a href="https://www.benzinga.com/m-a/24/05/39066034/why-is-medical-coating-specialist-surmodics-trading-higher-on-wednesday">merger agreement with GTCR on May 29, 2024.</a>
Under the terms of the deal, GTCR will acquire all outstanding shares of Surmodics for $43.00 per share, resulting in an equity valuation of approximately $627 million.
The transaction is expected to be financed through a combination of equity and debt financing from GTCR.
If completed, Surmodics will become a privately held entity and its shares will no longer be listed on the Nasdaq Global Select Market. Shareholders approved the merger on August 13, 2024.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SRDX stock has lost over 1.76% in the past year.
Price Action: SRDX shares are trading lower by 4.76% to $28.21 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44146094/wall-street-awaits-trumps-tariff-decision-digests-mixed-economic-data-whats-driving-markets-wednesday" target="_blank" rel="noreferrer noopener">Wall Street Awaits Trump&#8217;s Tariff Decision, Digests Mixed Economic Data: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo: Shutterstock

Equities

Health Care

Markets

Movers

General

Why Surmodics Stock Is Falling On Friday

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's ("FTC" or the "Agency") announcement that it will challenge the proposed acquisition of Surmodics (the "Merger") by funds affiliated with GTCR LLC ("GTCR"), which have an equity investment in Biocoat Inc., a maker of medical coatings:
"Surmodics respectfully disagrees with the FTC's decision and remains committed to completing the Merger. Surmodics remains confident in both its rationale for the Merger and the value it will bring to all stakeholders, including shareholders, customers and patients. We have worked constructively with the FTC over the last several months to secure regulatory approval for the Merger and are disappointed by its decision to initiate litigation, as the Merger is pro-competitive."
Surmodics intends to vigorously defend this case in court in order to complete the Merger.
Additional Information About the Pending Acquisition of Surmodics by funds affiliated with GTCR
On May 29, 2024, Surmodics announced it had entered into a definitive merger agreement to be acquired by funds affiliated with GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the merger agreement, an affiliate of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million. The transaction will be financed through a combination of committed equity from funds affiliated with GTCR and committed debt financing. Upon completion of the transaction, Surmodics will be a privately held company and its common stock will no longer be listed on The Nasdaq Global Select Market.
The Merger was approved by Surmodics' shareholders at a special meeting held on August 13, 2024.

Government

Regulations

Surmodics Vows to Fight FTC Lawsuit Blocking $627M Acquisition by GTCR

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Radiopharm Theranostics ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>)</h3>
<ul>
<li>On Jan. 10, Radiopharm Theranostics announced it will execute a private placement and will raise $5 million in proceeds. The company' stock fell around 11% over the past five days and has a <a href="https://www.benzinga.com/quote/RADX">52-week low of $3.71</a>.</li>
<li>RSI Value: 27.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RADX Price Action: Shares of RADX closed at $4.40 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1">RADX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50.png" alt="" class="wp-image-768930" style="width:479px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50-768x712.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
<h3 class="wp-block-heading">Surmodics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>)</h3>
<ul>
<li>On Feb. 3, Surmodics reported successful early clinical use of Pounce XL Thrombectomy System for non-surgical clot removal in iliac and femoral arteries. The company's stock fell around 15% over the past month and <a href="https://www.benzinga.com/quote/SRDX">has a 52-week low</a> of $25.21.</li>
<li>RSI Value: 29.9</li>
<li>SRDX Price Action: Shares of Surmodics gained 0.7% to close at $33.85 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1">SRDX stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9.png" alt="" class="wp-image-768931" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9-768x697.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul>
<li>On Feb. 4, Merck &amp; Co reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for business development transactions and operational strength primarily drove the increase. The company's stock fell around 10% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/MRK">low of $87.33</a>.</li>
<li>RSI Value: 28.4</li>
<li>MRK Price Action: Shares of Merck fell 1.2% to close at $89.67 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1">MRK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="882" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51.png" alt="" class="wp-image-768933" style="width:525px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51-768x725.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43492050/top-3-financial-stocks-that-may-rocket-higher-this-quarter">Top 3 Financial Stocks That May Rocket Higher This Quarter</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

RADX

Top 3 Health Care Stocks You'll Regret Missing This Month

With the addition of the Pounce&#x2122; XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the Pounce&#x2122; Thrombectomy Platform can now rapidly remove acute or chronic clot throughout the lower extremity without aspiration, thrombolysis, or capital equipment.

Surmodics Reports Successful Early Clinical Use Of Pounce XL Thrombectomy System For Non-Surgical Clot Removal In Iliac And Femoral Arteries

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce&#x2122; XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR.
Surmodics Pounce Thrombectomy systems are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The new Pounce XL Thrombectomy System is indicated for use in vessels ranging from 5.5–10 mm in diameter, sizes typical of iliac and femoral arteries. The Pounce XL System complements the Pounce and Pounce LP Thrombectomy Systems, which are indicated for 3.5–6 mm and 2–4 mm vessels, respectively.

Surmodics Expands Thrombectomy Line, FDA-Cleared Pounce XL Thrombectomy System Targets Larger Arteries, Full Launch Coming Soon

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Surmodicsto Hold

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) released its Q1 earnings on Thursday, January 30, 2025 at 07:00 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Surmodics beat estimated earnings by 67.0%, reporting an EPS of $-0.04 versus an estimate of $-0.12.
Revenue was down $630 thousand from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.16, leading to a 0.0% increase share price change the next day.
Here's a look at Surmodics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.33</td>
<td>-0.32</td>
<td>-0.3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.27</td>
<td>0.07</td>
<td>0</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>30.39M</td>
<td>30.01M</td>
<td>28.84M</td>
<td>29.64M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>33.23M</td>
<td>30.34M</td>
<td>31.96M</td>
<td>30.55M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Surmodics <a href="https://www.benzinga.com/quote/SRDX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Surmodics Earnings Analysis: Q1 Recap

CORRECTION: Surmodics reported Q4 financial results on Nov. 6

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Hold.

Needham Reiterates Hold on Surmodics

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.29) by 55.17 percent. This is a 124.53 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $33.23 million which beat the analyst consensus estimate of $30.40 million by 9.32 percent. This is a 18.80 percent increase over sales of $27.97 million the same period last year.

Surmodics Q4 2024 Adj EPS $(0.13) Beats $(0.29) Estimate, Sales $33.23M Beat $30.40M Estimate

Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal treatment post Pounce&#x2122; System use.
Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C.

Biotech

Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post Pounce System Use

Surmodics expects to initiate limited market release for the Pounce XL Thrombectomy System in the first half of 2025, with commercialization planned following the completion of the limited market release.

Surmodics Receives FDA 510(k) Clearance For Pounce XL Thrombectomy System

A downtrend has been apparent in SurModics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srdx#NASDAQ">SRDX</a>) lately with too much selling pressure. The stock has declined 5.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company&#39;s ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.
<h2>Guide to Identifying Oversold Stocks</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Why SRDX Could Bounce Back Before Long</h2>
The RSI reading of 21.52 for SRDX is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for SRDX has increased 4.1%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, SRDX currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2332007/down-5-46-in-4-weeks-here-s-why-surmodics-srdx-looks-ripe-for-a-turnaround?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2332007">To read this article on Zacks.com click here.</a>

Technicals

Small Cap

Tech

Down -5.46% in 4 Weeks, Here's Why SurModics Looks Ripe for a Turnaround

SurModics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srdx#NASDAQ">SRDX</a>) has been on a downward spiral lately with significant selling pressure. After declining 6.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
<h2>Guide to Identifying Oversold Stocks</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Why SRDX Could Bounce Back Before Long</h2>
The RSI reading of 15.57 for SRDX is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
<img alt="3-month RSI Chart for SRDX" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/SRDX_RCI14.jpeg" style="height:auto; width:100%" title="" />
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering SRDX in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 4.9% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, SRDX currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2322514/surmodics-srdx-loses-6-29-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2322514">To read this article on Zacks.com click here.</a>

SurModics Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Surmodics Q3 2024 Adj. EPS $(0.27) Beats $(0.33) Estimate, Sales $30.341M Beat $30.006M Estimate

Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce&nbsp;and Pounce&nbsp;Venous Thrombectomy Systems.

Contracts

Surmodics Secures A Group Purchasing Agreement For Thrombectomy Products With Premier, Inc. ; No Terms Disclosed

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.4, a high estimate of $71.00, and a low estimate of $43.00. Experiencing a 16.27% decline, the current average is now lower than the previous average price target of $59.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1717088457_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Surmodics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Announces</td>
<td>Hold</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>James Sidoti</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Neutral</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$47.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Surmodics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Surmodics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Surmodics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Surmodics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SRDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Surmodics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Surmodics</h2>
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
<h3>A Deep Dive into Surmodics's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Surmodics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 17.5%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Surmodics's net margin is impressive, surpassing industry averages. With a net margin of 0.77%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Surmodics's ROE excels beyond industry benchmarks, reaching 0.2%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Surmodics's ROA excels beyond industry benchmarks, reaching 0.14%. This signifies efficient management of assets and strong financial health.
Debt Management: Surmodics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.27.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Surmodics: Insights From 5 Financial Analysts

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRCL, IBTX, AGS, SRDX on Behalf of Shareholders

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

Comments

Surmodics

Surmodics (SRDX) 옵션

Surmodics (NASDAQ:SRDX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌